Song JunMei, Liu Ting, Huang Qiulin, Lv YuQing, Wen YaJing, Wang RenSheng, Bie Jun
Department of Oncology, Beijing Anzhen Nanchong Hospital, Capital Medical University (Nanchong Central Hospital), 637000, Nanchong, Sichuan, China.
The Second Clinical Medical College of North, Sichuan Medical College, 637000, Nanchong, Sichuan, China.
Support Care Cancer. 2025 Feb 26;33(3):226. doi: 10.1007/s00520-025-09280-5.
This study aimed to evaluate the prognostic value of the pre-treatment prognostic nutritional index (PNI) in patients with locally advanced nasopharyngeal carcinoma (LANPC) treated with endostar combined with concurrent chemoradiotherapy (ECCRT).
Clinical data from 92 patients with LANPC who underwent ECCRT between May 2015 and December 2020 were retrospectively analyzed. The PNI was calculated using peripheral blood samples taken 1 week before treatment. The optimal cut-off value for PNI was determined via receiver operating characteristic (ROC) curve analysis based on overall survival (OS). Patients were categorized into high PNI and low PNI groups. The Kaplan-Meier method assessed the impact of PNI on survival, while univariate and multivariate Cox regression analyses identified independent risk factors affecting patient survival.
The optimal cut-off value of PNI was 50.05. The 3-year OS, progression-free survival (PFS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRRFS) rates were 91.07% vs. 75.00% (P = 0.002), 83.93% vs. 66.67% (P = 0.015), 89.29% vs. 69.44% (P = 0.004), and 94.64% vs. 91.67% (P = 0.668) in the high PNI and low PNI groups, respectively. A low PNI was associated with shorter OS (HR = 3.592, P = 0.004), PFS (HR = 2.890, P = 0.017), and DMFS (HR = 3.826, P = 0.008). Multivariate analysis revealed that PNI was an independent prognostic factor for OS, PFS, and DMFS.
The PNI may serve as a valuable prognostic predictor for patients with LANPC receiving ECCRT, aiding clinicians in selectively providing multimodal interventions to optimize survival outcomes.
本研究旨在评估治疗前预后营养指数(PNI)在接受恩度联合同步放化疗(ECCRT)的局部晚期鼻咽癌(LANPC)患者中的预后价值。
回顾性分析2015年5月至2020年12月期间接受ECCRT的92例LANPC患者的临床资料。PNI采用治疗前1周采集的外周血样本计算。基于总生存期(OS),通过受试者工作特征(ROC)曲线分析确定PNI的最佳临界值。患者被分为高PNI组和低PNI组。采用Kaplan-Meier法评估PNI对生存的影响,单因素和多因素Cox回归分析确定影响患者生存的独立危险因素。
PNI的最佳临界值为50.05。高PNI组和低PNI组的3年总生存期(OS)、无进展生存期(PFS)、无远处转移生存期(DMFS)和无局部复发生存期(LRRFS)率分别为91.07%对75.00%(P = 0.002)、83.93%对66.67%(P = 0.015)、89.29%对69.44%(P = 0.004)和94.64%对91.67%(P = 0.668)。低PNI与较短的OS(HR = 3.592,P = 0.004)、PFS(HR = 2.890,P = 0.017)和DMFS(HR = 3.826,P = 0.008)相关。多因素分析显示,PNI是OS、PFS和DMFS的独立预后因素。
PNI可能是接受ECCRT的LANPC患者有价值的预后预测指标,有助于临床医生有选择地提供多模式干预措施以优化生存结局。